




# Coming together to better diagnose liver diseases, like NASH

Perspectum Diagnostics and QuintilesIMS have established a partnership to help optimize the value of your NASH products by enhancing and accelerating the planning, execution and patient experience of clinical trials.

<p>Often referred to as the “silent killer,” NASH is an untreated liver condition that affects millions of people.</p> 	<p>Current diagnosis of NASH using liver biopsies is painful, invasive, inconsistent and expensive.</p>	<p>Healthcare ecosystems are strained with the complexity of metabolic indications.</p>
<p>The market for NASH treatments is expected to reach \$35 to \$40 billion by 2025, with estimated demand of 60,000 clinical trial participants over the next 4 years. (Source: Deutsche Bank)</p>	<p>It is possible to improve the diagnosis and treatment of NASH in ways that are less invasive, more reliable and significantly less expensive.</p> 	<p>Supporting diagnostic technologies and health economic evidence can be used to facilitate reimbursement and maximize product value.</p> 

Meeting the demands of NASH clinical trials requires partners with breakthrough technology solutions, global clinical operations excellence, deep relationships with industry leaders and stakeholders and the capability to identify and recruit trial participants to better predict treatment pathways beyond approval.

**Perspectum Diagnostics** offers state-of-the-art MR-based Liver*MultiScan* imaging analysis to provide non-invasive quantification of liver fat, iron, and fibro-inflammatory disease. We have created value for sponsors through utilizing Liver*MultiScan* to reduce their operational costs of development and the burden on patients, investigators and sites in trials to improve NASH outcomes.

**QuintilesIMS** is a leading global healthcare provider of integrated information and technology-enabled services. We leverage therapeutic knowledge and real-world data to understand how to identify and connect with patients in a clinical setting to help accelerate clinical outcomes.

Liver*MultiScan* metrics have been used to **support regulatory submissions** as an endpoint in clinical trials to the **FDA** and **EU** regulators

Perspectum has world-renowned, proven experience in global NASH trials using our highly **accurate** and **reproducible Quantitative Analysis Services**

We have **24** prime sites and **>1,200** partner sites and **>38,000** partner investigators

We helped develop or commercialize **85%** of the **Top 20** best-selling **gastroenterology** products of 2015

Perspectum’s **Hub and Spoke model** has created immediate access to viable NASH patients from **untapped communities**

Perspectum provides an improved patient experience through **non-invasive imaging** technology that scans the whole liver, reducing screen failure rates

We leverage our access to **>530M** patient records across **30+** countries in support of clinical trials



Learn more about the QuintilesIMS and Perspectum Diagnostics partnership. [clinical@quintilesims.com](mailto:clinical@quintilesims.com) and [info@perspectum-diagnostics.com](mailto:info@perspectum-diagnostics.com).